Volume 73, Issue 6, Pages (June 2018)

Slides:

Advertisements

Similar presentations

Volume 56, Issue 5, Pages (November 2009)

Advertisements

Volume 72, Issue 1, Pages (July 2017)

The PSA Era is not Over for Prostate Cancer

Volume 54, Issue 2, Pages (August 2008)

Volume 68, Issue 2, Pages (August 2015)

Volume 62, Issue 1, Pages (July 2012)

Volume 57, Issue 1, Pages (January 2010)

Volume 50, Issue 1, Pages (July 2006)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

European Urology Focus

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 53, Issue 4, Pages (April 2008)

Volume 64, Issue 6, Pages (December 2013)

Volume 71, Issue 1, Pages (January 2017)

Volume 54, Issue 4, Pages (October 2008)

Volume 51, Issue 4, Pages (April 2007)

Volume 73, Issue 1, Pages (January 2018)

Volume 70, Issue 4, Pages (October 2016)

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 4, Pages (April 2013)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

Volume 54, Issue 4, Pages (October 2008)

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 68, Issue 5, Pages (November 2015)

Volume 70, Issue 3, Pages (September 2016)

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

Volume 62, Issue 1, Pages (July 2012)

Volume 73, Issue 4, Pages (April 2018)

Volume 66, Issue 6, Pages (December 2014)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 53, Issue 4, Pages (April 2008)

Volume 62, Issue 4, Pages (October 2012)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 65, Issue 6, Pages (June 2014)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 67, Issue 6, Pages (June 2015)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 5, Pages (November 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 53, Issue 1, Pages (January 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 59, Issue 4, Pages (April 2011)

Volume 72, Issue 1, Pages (July 2017)

European Urology is “Your” Journal

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 53, Issue 5, Pages (May 2008)

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Volume 68, Issue 2, Pages (August 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 51, Issue 2, Pages (February 2007)

Does PSA Testing Influence the Natural History of Prostate Cancer?

Presentation transcript:

Volume 73, Issue 6, Pages 961-967 (June 2018) Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening Melissa Assel, Anders Dahlin, David Ulmert, Anders Bergh, Pär Stattin, Hans Lilja, Andrew J. Vickers European Urology Volume 73, Issue 6, Pages 961-967 (June 2018) DOI: 10.1016/j.eururo.2017.10.004 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Flow diagram of the inclusion process for the Malmö Preventive Project (MPP) and the Malmö Diet and Cancer (MDC) cohorts. PSA, prostate-specific antigen. European Urology 2018 73, 961-967DOI: (10.1016/j.eururo.2017.10.004) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Flow diagram of the inclusion process for the Västerbotten Intervention Project (VIP) cohort. PSA, prostate-specific antigen. European Urology 2018 73, 961-967DOI: (10.1016/j.eururo.2017.10.004) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 3 Probability of high-grade (solid line) and low-grade (dashed line) prostate cancer by lead time among participants aged 45–70 yr with prostate-specific antigen of 3.0–10 ng/ml at baseline blood draw. The shaded area denotes the shape of the distribution of lead times rescaled for presentation. PCa, prostate cancer; PSA, prostate-specific antigen. European Urology 2018 73, 961-967DOI: (10.1016/j.eururo.2017.10.004) Copyright © 2017 European Association of Urology Terms and Conditions